Company Future Sales Volume: Exact Sciences Inc. (EXAS)

Exact Sciences growth is based on partnerships with oncology centers to implement Cologuard screening. Projected sales volume dynamics confirm this trajectory, where 3.25 serves as the current metric level. Stability is ensured by top-tier geneticists and robust patent protection, bolstered by the integration of tests into the Medicare system, which limits market entry for new players.

EXAS - Exact Sciences Inc. Projected Sales Volume over the range 07/04/2022 - 04/04/2026

Comprehensive metric breakdowns and analytics for Exact Sciences Corp (EXAS)

- stock quotes and analyst forecast:

Stock Price Exact Sciences|EXAS - Average Forecast Price

- company stock exchange capitalization indicators:

Market Valuation Exact Sciences Corp|EXAS - Business Value

- issuer book value statistics:

Book Value per Share Exact Sciences|EXAS - Book Capitalization|Market Capitalization to Book Value Ratio exactsciences.com|EXAS - Cumulative Company Assets

- business debt structure and liquidity details:

- earnings and market ratios statistics:

EXAS - Net Financial Result|Projected Future Earnings Exact Sciences|EXAS - Market Cap to Earnings|Future Price to Earnings Exact Sciences Corporation|EXAS - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Exact Sciences Corp|EXAS - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Exact Sciences|EXAS - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months exactsciences.com|EXAS - Expected net earnings per share growth this year|Earnings growth forecast for next year Exact Sciences

- sales volume and revenue indicators:

EXAS - Company Total Revenue|Company Future Sales Volume Exact Sciences|EXAS - Market Cap to Revenue Ratio|Forward P/S Multiple Exact Sciences Corp

Fundamental valuation:EXAS Exact Sciences

Amid intense competition in the US market, Exact Sciences (EXAS) is scaling its early cancer detection platforms, which necessitates precise monitoring of commercial potential. This metric measures projected revenue on a daily basis, allowing investors to distinguish systemic decline from temporary asset undervaluation by assessing the balance of reliability and return through the company's planned sales dynamics.

Main competitors